On November 7th, 2002, SmallCap Digest initiated coverage on a small, Virginia-based biotech named CEL-SCI (AMEX: CVM) which has developed some amazing --and potentially life-saving-- immunotherapies for the treatment of cancer and viral disease. CEL-SCI’s stock was then trading at 18 cents. Much has transpired in the ensuing months. Not the least of which was an enormous profit for those investors who heeded our initial CEL-SCI Trading Alert and bought into the shares early. 

To whit: buying a share of CVM now would cost you roughly $1.70—the shares have posted a gain of 750 percent in less than a year.

And now, the next bolt of lightning.

Here’s the second potential bolt of lightning: a purchase of the shares of cancer detection concern BioCurex (OTCBB: BOCX), currently trading at 16-17 cents, has, we strongly believe, the potential to return handsomely over the next 12 months. Our buy range would ideally be below 20 cents, but should the shares move into the low 20-cent range, purchases should still be made, given, as you will see, the potential of the company and its technologies. 

Without putting too fine a point on BioCurex’s product efficacies, they could very well revolutionize cancer diagnosis and early prediction. And, most importantly, save lives.

The salient points investors need to know about BioCurex are:

• Focused on the healthcare solutions/diagnostics  space—a $10 billion market expected to grow by double digits annually over the next half decade;
• Cutting edge patented/proprietary technology for cancer diagnosis, tumor imaging and treatment;
• Identifies the presence of cancer through detection of a biomarker known as RECAF. Research indicates BioCurex’s products may detect cancer much earlier than existing technologies; 
• A sensitivity (detection) rate of 90-100 percent of cancers through either blood, tissue biopsies or other specimens tested;
• High sensitivity for breast and lung cancer—the most common cancer varieties;
• No competitor approaches the detection rate of BioCurex’s diagnostic products;
• BioCurex holds the patent for the RECAF biomarker*;
• Early cancer diagnosis cuts healthcare costs significantly—an extremely important benefit as those costs continue to rise.

This is very cool –and important--stuff…

One of the reasons BioCurex has the patent on the RECAF biomarker is simple: the two doctors who initiated the field of cancer markers are on BOCX’s Scientific Advisory Board. The others in that group are experts in both the science of biomarkers and cancer. BioCurex’s management, too, has significant experience in biotechnology and has worked to develop both business opportunities and raise awareness of the early detection of cancers through their identifying biomarkers.

BioCurex has been granted FDA clearance for its Histo-RECAF kit for cancer testing of tissue sections and biopsies.

In a study that included 147 normal samples and 91 cancer samples, Histo-RECAF delivered a 95 percent detection rate for various forms of cancer, including cervix, lung, head and neck, among others. BioCurex’s test sensitivity is 100 percent for breast cancer. Current marker tests detect only 35-50 percent of breast cancer cases.

Blood Test for cancer may be even more exciting…

As well as its tissue specific test, Histo-RECAF, BioCurex has developed a blood specific testing product: Serum-RECAF. The early results for the blood test are just as exciting as those for the tissue test in detecting cancer markers. The market potential for early cancer detection technology is, frankly, massive. Consider that with a single drop of blood taken at a routine annual medical examination, the high accuracy of the Serum-RECAF test may immediately detect the present of –-hopefully, early stage-- cancer in the body. The technology can also be applied to pinpoint the exact location of a cancer.

During the research process, BioCurex’s Serum-RECAF blood test was employed on 140 normal blood samples and 140 ovarian cancer blood samples. The results were impressive: ovarian cancer sensitivity was 90 percent. Currently, the prevalent test for ovarian cancer is Japan’s Fujirebio Diagnostic Inc.’s CA-125 which has a sensitivity of only 77 percent. 

The Potential is now.

The commercial scope for both Histo-and Serum-RECAF tests is obvious: the aggregate annual market is in excess of $2 billion. Ovarian cancer diagnosis alone represents a $200 million market. BioCurex plans to capture 25 percent of that specific market (among others) within 3 years. 

BioCurex’s technology has extraordinarily diverse and broad potential applications to detect and diagnose virtually all types of cancer.

SmallCap Digest will bring you more details on BioCurex as they unfold. In the meantime, investors should strongly consider an initial purchase of the shares.

Enclosed with this Alert is a Press Release posted Thursday, attesting to both the potential and international nature of BioCurex’s products.
 
 

Got comments, questions or suggestions? Send 'em on over: Editor@smallcapdigest.net

Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.smallcapdigest.net/compensation_disclosure.html for our full compensation disclosure and http://www.smallcapdigest.net/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company.

All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with  which the editor is affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.